I also believe so NZ Trade, the market value for the scar prevention/repair is much larger than blood cancer. If 6302 can deliver further positive result the opportunities should be wide open to the company, not only the cosmetic/skin industry, but also the Wound Care medical/device providers will be very interested in this area. Avita Medical (AVH), which is also built by Fiona wood, is now FDA approved and selling into US market, however the sales began to slow and shows some saturation for their Recell products. If they can (only my opinion) combines Syntara's 6302 solution into their existing product pipeline, the market will be further expanded (Burn wound care, skin repair, and Scar prevention/treatment). Not saying Avita will take over Syntara, just saying there are many on-watchers are keeping a close eye on SNT's trail result.
For all those expected near term news flow,3-4 in a roll next in few weeks, I am particularly interested in the next Trial pan of 6302.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)